Drugs for diabetes: part 4 acarbose

Arungarinathan, G., McKay, G. A. and Fisher, M. (2011) Drugs for diabetes: part 4 acarbose. British Journal of Cardiology, 18(2), pp. 78-81.

Full text not currently available from Enlighten.

Publisher's URL: http://bjcardio.co.uk/2011/04/drugs-for-diabetes-part-4-acarbose/


Acarbose is an alpha-glucosidase inhibitor acting in the gastrointestinal tract producing modest reductions in postprandial hyperglycaemia, with negligible risk of hypoglycaemia and weight gain. In a subgroup of the United Kingdom Prospective Diabetes Study (UKPDS), acarbose showed glycaemic benefits irrespective of the type of concomitant therapy. Acarbose was shown to produce a significant reduction in the progression to diabetes in patients with impaired glucose tolerance in the Study to Prevent Non-Insulin-Dependent Diabetes Mellitus (STOP-NIDDM) trial, and in a post-hoc analysis of STOP-NIDDM a reduction in cardiovascular events was observed. Gastrointestinal side effects are the main limiting factor in clinical practice, leading to high rates of non-compliance and discontinuation.

Item Type:Articles
Glasgow Author(s) Enlighten ID:McKay, Dr Gerard
Authors: Arungarinathan, G., McKay, G. A., and Fisher, M.
College/School:College of Medical Veterinary and Life Sciences > School of Medicine, Dentistry & Nursing
Journal Name:British Journal of Cardiology
Journal Abbr.:Br J Cardiol
Publisher:MediNews Limited
ISSN (Online):1753-4313

University Staff: Request a correction | Enlighten Editors: Update this record